Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02112994 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency
A Phase 2 study of Lysosomal Acid Lipase Deficiency, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 19
- Study locations
NCT02112994: Completed Phase 2 study of Lysosomal Acid Lipase Deficiency, sponsored by Alexion Pharmaceuticals.
NCT02112994 is a Phase 2 study of Lysosomal Acid Lipase Deficiency that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 31 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 19 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02112994, a Phase 2 study of Lysosomal Acid Lipase Deficiency, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 19
- Study locations
Study Summary
This study evaluated the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency (LAL-D).
Primary Outcome
The number of participants experiencing severe TEAEs is presented for participants who received sebelipase alfa in this open-label study. Adverse events (AEs) information was obtained at each scheduled contact with the participant (or participant's parent or legal guardian). An AE was defined as any untoward medical occurrence that did not require a causal relationship with study drug administration. An AE could have been any unfavorable and unintended sign, symptom, or disease temporally associ
Conditions Studied
Interventions
- DRUG Sebelipase Alfa
Study Locations (19)
Other
- - Westmead
- - Brussels
- - São Paulo
- - Zagreb
- - Copenhagen
- - Freiburg im Breisgau
- - Padua
- - Mexico City
- - Amsterdam
- - Moscow
- - A Coruña
- - Barcelona
- - Madrid
- - Balcalı
- - Birmingham
Illinois
- - Chicago
Louisiana
- - Shreveport
Ohio
- - Cincinnati
Nova Scotia
- - Halifax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-06-24 |
| Est. Completion | 2017-12-28 |
| Phase | Phase 2 |
What the finished NCT02112994 record still lists
NCT02112994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Lysosomal Acid Lipase Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Sebelipase Alfa is the first listed.
NCT02112994 lists 19 locations in 5 states (Other, Illinois, Louisiana).
Frequently Asked Questions
What is clinical trial NCT02112994 about?
NCT02112994 is a clinical study titled "Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency". This study evaluated the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency (LAL-D).
What is the current status of trial NCT02112994?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2014-06-24. Estimated completion is 2017-12-28.
What conditions does trial NCT02112994 study?
This clinical trial studies the following conditions: Lysosomal Acid Lipase Deficiency.
What interventions are being tested in trial NCT02112994?
The interventions under investigation include: Sebelipase Alfa (DRUG).
Who is sponsoring clinical trial NCT02112994?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02112994 being conducted?
This trial has 19 study locations across Illinois, Louisiana, Ohio, Nova Scotia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lysosomal Acid Lipase Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02112994's enrollment target sits among peer trials
31 1578th of 2000 higher than 419 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI